{"id":6626,"date":"2026-07-13T11:03:01","date_gmt":"2026-07-13T11:03:01","guid":{"rendered":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/?p=6626"},"modified":"2026-07-13T11:03:05","modified_gmt":"2026-07-13T11:03:05","slug":"measure-up-atopic-dermatitis-study","status":"publish","type":"post","link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/measure-up-atopic-dermatitis-study\/","title":{"rendered":"0The Measure Up 1 and Measure Up 2 Studies: Upadacitinib for Atopic Dermatitis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition that can cause intense itching, dry skin, redness and repeated flare-ups. If you are living with moderate-to-severe eczema, these symptoms can affect your comfort, sleep, confidence and the way you manage everyday activities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">When eczema becomes more difficult to control, topical treatments alone may not always provide enough relief. You may need a treatment approach that targets the underlying inflammation, helping to reduce flare-ups, improve skin health and give you better control over symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up 1 and Measure Up 2 trials evaluated upadacitinib, a selective JAK1 inhibitor, in adults and adolescents with moderate-to-severe atopic dermatitis. These studies looked at how well the medication improved eczema severity, reduced itching and supported better quality of life while maintaining an acceptable safety profile.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Understanding the design, results and clinical importance of these trials can help you make more informed decisions about your eczema treatment. The findings give you and your clinician valuable information when considering whether upadacitinib may be a suitable option within your personalised management plan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Is Upadacitinib<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Upadacitinib is an oral treatment that selectively inhibits Janus kinase 1 (JAK1), an enzyme involved in the immune signalling pathways that contribute to atopic dermatitis. If you are living with moderate-to-severe eczema, understanding how this medication works can help you see why it may be considered as part of your treatment options.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The medicine targets specific inflammatory pathways linked to eczema symptoms, including cytokines that contribute to itching, redness and skin inflammation. For you, this targeted approach may help reduce the activity of these pathways while improving control of troublesome symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Selective JAK1 inhibition is designed to focus on a specific part of the immune response rather than affecting multiple pathways at once. This may help reduce some of the risks associated with broader JAK inhibitors, although your clinician will still consider your individual health factors before recommending treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Rationale for the Measure Up Trials<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up trials were designed to evaluate the effectiveness and safety of upadacitinib in people with moderate-to-severe atopic dermatitis. If you are considering this treatment, these studies provide important evidence about how well the medication works and how it may fit into your eczema management plan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The trials compared different doses of upadacitinib with placebo to understand the most appropriate balance between treatment benefits and tolerability. For you, this type of comparison helps provide clearer information about which approach may offer the best symptom control while maintaining safety.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The large number of participants included in the studies strengthened the reliability of the findings and helped researchers understand how the treatment may perform across different groups of people. This means you can have greater confidence in the evidence supporting upadacitinib as a treatment option for suitable patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Evidence Note<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up 1 and Measure Up 2 studies were international Phase III randomised, double-blind, placebo-controlled clinical trials evaluating oral upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis. Both trials demonstrated significant improvements in eczema severity (EASI 75), Investigator&#8217;s Global Assessment (vIGA-AD 0\/1), itch reduction and quality of life compared with placebo at Week 16, with benefits maintained during longer-term follow-up.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Study Design: Measure Up 1<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Measure Up 1 was a randomised, double-blind, placebo-controlled trial designed to assess the effectiveness and safety of upadacitinib in people with moderate-to-severe atopic dermatitis. If you are exploring treatment options for eczema, understanding the design of this study can help you see how researchers evaluated the benefits and risks of the medication.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The trial included adults and adolescents with significant eczema severity, measured using tools such as the Eczema Area and Severity Index (EASI) and Investigator\u2019s Global Assessment (IGA) scores. These criteria helped ensure that participants had a level of disease where you could meaningfully assess whether the treatment improved symptoms, skin appearance and overall control of eczema.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The primary endpoint was the proportion of participants achieving EASI 75 at week 16, which represents a 75% improvement in eczema severity from the start of treatment. For you, this outcome provides a useful indication of how effective upadacitinib may be when used as part of a personalised eczema management plan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Study Design: Measure Up 2<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Measure Up 2 followed a similar design to Measure Up 1, providing an independent confirmation of the findings. If you are looking at the evidence behind upadacitinib, having results from a separate trial helps you understand how consistent the treatment effects are.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study used similar inclusion criteria and endpoints to assess treatment response and safety across different participant groups. This allowed researchers to compare results more reliably and determine whether you could expect similar benefits from the therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By replicating the study approach, Measure Up 2 strengthened the overall evidence supporting upadacitinib. For you, this provides greater confidence that the reported improvements and safety findings are based on robust clinical data.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Feature<\/strong><\/td><td><strong>Measure Up 1<\/strong><\/td><td><strong>Measure Up 2<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Phase<\/td><td>III<\/td><td>III<\/td><\/tr><tr><td>Design<\/td><td>Randomised, double-blind, placebo-controlled<\/td><td>Randomised, double-blind, placebo-controlled<\/td><\/tr><tr><td>Participants<\/td><td>Adults and adolescents<\/td><td>Adults and adolescents<\/td><\/tr><tr><td>Treatment<\/td><td>Upadacitinib 15 mg or 30 mg<\/td><td>Upadacitinib 15 mg or 30 mg<\/td><\/tr><tr><td>Primary endpoint<\/td><td>EASI 75 at Week 16<\/td><td>EASI 75 at Week 16<\/td><\/tr><tr><td>Follow-up<\/td><td>Up to Week 52<\/td><td>Up to Week 52<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Patient Population<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Participants in the Measure Up trials had persistent moderate-to-severe atopic dermatitis for at least six months. If you have been living with ongoing eczema symptoms, this reflects the type of long-term condition the researchers aimed to study.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Most participants had previously used topical treatments, while their experience with systemic therapies varied. This allowed the trials to assess how upadacitinib worked in people with different treatment backgrounds and helped you understand where this medication may fit within eczema care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The inclusion criteria ensured that participants had significant disease severity, allowing researchers to measure meaningful clinical improvements. For you, this means the findings are more relevant if your eczema has been difficult to control with standard treatments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Dosing Regimens<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Upadacitinib was given as an oral tablet taken once daily at either a 15 mg or 30 mg dose in the Measure Up trials. If you are considering this treatment, the convenience of a once-daily tablet may make it easier to fit into your routine compared with injectable systemic therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This simple dosing schedule can support better adherence because it avoids the need for regular injections or clinic visits. For you, having a more convenient treatment option may help you maintain consistency with your eczema management plan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The choice of dose is based on balancing treatment effectiveness with tolerability. Your clinician will consider factors such as the severity of your eczema, your response to treatment and your overall health when deciding which dose is most suitable for you.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Primary Endpoint: EASI 75<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">EASI 75 refers to a 75% improvement in eczema severity compared with the beginning of treatment. If you have moderate-to-severe atopic dermatitis, achieving EASI 75 would mean a significant reduction in your symptoms and visible signs of eczema.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This measure is widely used in eczema research because it provides a consistent way to assess whether a treatment is making a meaningful difference. For you, it helps show how effectively a therapy may reduce inflammation, redness, itching and other symptoms that affect your daily life.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up trials used EASI 75 as the primary endpoint to evaluate the effectiveness of upadacitinib. This allowed researchers to clearly assess the treatment\u2019s impact and understand how much improvement you may expect during the early stages of therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Secondary Endpoints<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up trials also assessed several secondary outcomes, including EASI 90, EASI 100, itch reduction and improvements in Dermatology Life Quality Index (DLQI) scores. If you are considering upadacitinib, these measures help show the wider benefits you may experience beyond basic symptom improvement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">EASI 90 and EASI 100 assess near-complete or complete skin clearance, while itch scores and quality-of-life measures show how treatment affects your daily experience of eczema. For you, these outcomes provide a clearer picture of whether a treatment can improve both your skin and overall wellbeing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Safety and tolerability were also important parts of the secondary analyses. This information helps you and your clinician understand the potential benefits and risks when deciding whether upadacitinib is the right treatment option for you.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Key Findings: Efficacy at Week 16<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At week 16, both Measure Up trials showed that upadacitinib achieved significantly higher EASI 75 response rates compared with placebo. If you are looking for an effective treatment for moderate-to-severe eczema, these findings suggest that the medication can provide meaningful improvements within a relatively short period.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Many patients also achieved EASI 90 and EASI 100 responses, indicating near-complete or complete skin clearance. For you, this level of improvement could mean fewer visible symptoms, reduced discomfort and better control of your eczema.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These results demonstrate that upadacitinib can deliver rapid and clinically meaningful improvements for people with moderate-to-severe atopic dermatitis. With improved skin control, you may experience less disruption to your daily activities and overall quality of life.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Itch Reduction<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Itch is one of the most troublesome symptoms of atopic dermatitis and can have a major effect on your comfort, sleep and daily life. If you are living with persistent eczema, reducing itch can be one of the most important goals of treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upadacitinib produced significant reductions in pruritus scores within the first few weeks of therapy. For you, this early improvement may mean less irritation, fewer sleep disruptions and greater comfort throughout the day.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rapid itch relief is clinically meaningful because it addresses one of the symptoms that most affects quality of life. By improving itch control, upadacitinib may help you manage the wider impact of eczema on your wellbeing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Quality of Life Outcomes<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"559\" src=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T151504.800-1024x559.jpg\" alt=\"\" class=\"wp-image-6634\" srcset=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T151504.800-1024x559.jpg 1024w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T151504.800-980x535.jpg 980w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T151504.800-480x262.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Patients receiving upadacitinib reported improvements in Dermatology Life Quality Index (DLQI) scores, reflecting better daily functioning and increased confidence in social situations. If you are living with moderate-to-severe eczema, these improvements may help reduce the emotional and practical impact of ongoing symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Reductions in visible eczema and itch were linked with meaningful psychosocial benefits. For you, better symptom control may make everyday activities, sleep and interactions with others feel less affected by your condition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These findings show that clinical improvements are not only measured through skin scores but also through real-life benefits. Effective treatment can help improve both your skin health and overall quality of life.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Comparison Between Doses<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up trials showed that the higher dose of upadacitinib (30 mg) generally produced greater improvements in eczema severity and itch reduction compared with the 15 mg dose. If you are discussing treatment options with your clinician, these differences may help guide decisions about the most suitable dose for your condition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Both doses performed better than placebo, demonstrating that upadacitinib can provide meaningful benefits for people with moderate-to-severe atopic dermatitis. For you, the choice of dose will depend on factors such as symptom severity, treatment response and overall health considerations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Selecting the right dose involves balancing effectiveness with tolerability and personal preferences. Your clinician can help you decide which approach is most appropriate to achieve long-term control of your eczema while maintaining safety.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Research Insight<\/strong>: One of the most notable findings from the Measure Up programme was the rapid reduction in itch. Many participants experienced clinically meaningful improvements in pruritus within the first week of treatment. This early itch relief is particularly important because persistent itching is one of the symptoms that most affects sleep, mental wellbeing and quality of life in people with atopic dermatitis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Long-Term Efficacy<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Follow-up data from the Measure Up trials showed that the benefits of upadacitinib were maintained through 52 weeks. If you are looking for a treatment that provides lasting control, these findings suggest that the medication can continue to improve eczema symptoms over time.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Persistent improvements in skin clearance and quality of life indicate that upadacitinib may be a suitable option for long-term management of moderate-to-severe atopic dermatitis. For you, maintaining better symptom control could help reduce the impact of itching, inflammation and flare-ups on daily life.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Consistency is especially important when managing a chronic condition such as eczema. By following your treatment plan and attending regular reviews, you can work with your clinician to maintain long-term control and adjust treatment when needed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Safety Profile<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Upadacitinib was generally well tolerated in the Measure Up trials, with most reported side effects being mild to moderate. If you are considering this treatment for moderate-to-severe atopic dermatitis, these findings may reassure you that many participants were able to use the medication safely.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Common side effects included upper respiratory infections and headache. For you, it is important to understand that these events were usually manageable and did not lead to major safety concerns during the study period.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">No unexpected safety signals emerged during the trials. This supports the use of upadacitinib as an effective treatment option with a safety profile that can be monitored through appropriate clinical follow-up.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Laboratory Monitoring<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Laboratory monitoring is recommended during treatment with upadacitinib to help ensure your safety over the long term. If you are taking this medication for chronic eczema, routine blood tests can help your clinician identify any potential concerns early.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Selective JAK1 inhibition may offer a more targeted approach compared with broader immunosuppressive treatments, although regular monitoring remains important. For you, these checks provide reassurance that your treatment response and overall health are being carefully reviewed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Monitoring is particularly valuable when a medication is used over an extended period. By attending follow-up appointments and completing recommended tests, you can help ensure that your treatment remains both effective and appropriate for your needs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical Tip<\/strong>: Because upadacitinib is a Janus kinase (JAK) inhibitor, your dermatologist will usually review your medical history, vaccination status, cardiovascular risk factors and previous infections before treatment begins. Regular blood tests may also be recommended during treatment to help monitor safety.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Infection Risk<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Infections reported during the Measure Up trials were generally uncommon and mostly mild in severity. If you are considering upadacitinib for atopic dermatitis, these findings may reassure you that serious infection risks were not increased compared with placebo in the study population.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">No rise in serious or opportunistic infections was observed among participants receiving treatment. For you, this suggests that upadacitinib demonstrated a reassuring safety profile when used under appropriate clinical monitoring.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These results support the use of upadacitinib as a treatment option for suitable patients with moderate-to-severe atopic dermatitis. However, your clinician will still consider your individual health factors and monitor for any potential concerns during treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Cardiovascular and Thrombotic Considerations<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">No significant increase in cardiovascular events or thrombotic risks was reported in the Measure Up trials. If you are considering upadacitinib, these findings may provide some reassurance about its safety profile when used as part of your eczema treatment plan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, if you have existing cardiovascular risk factors or other health concerns, your clinician will need to assess your individual situation carefully. For you, regular monitoring and open discussions about your medical history can help ensure that treatment decisions remain appropriate.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This safety information is encouraging for the long-term management of atopic dermatitis. With personalised assessment and ongoing follow-up, you and your clinician can make informed decisions about whether upadacitinib is the right option for you.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Laboratory Abnormalities<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"559\" src=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152229.770-1024x559.jpg\" alt=\"\" class=\"wp-image-6636\" srcset=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152229.770-1024x559.jpg 1024w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152229.770-980x535.jpg 980w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152229.770-480x262.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Laboratory abnormalities reported during the Measure Up trials were generally minimal and temporary. If you are considering upadacitinib, these findings may reassure you that significant changes in routine blood tests were uncommon during treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Routine monitoring remains an important part of safe long-term therapy. For you, regular blood tests and follow-up appointments allow your clinician to identify any concerns early and ensure that the medication continues to be suitable.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Serious laboratory abnormalities were rare, supporting the use of upadacitinib as a manageable long-term treatment option. With appropriate monitoring, you and your clinician can balance the benefits of symptom control with ongoing safety.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Treatment Discontinuation<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Only a small number of patients discontinued upadacitinib because of adverse events during the Measure Up trials. If you are considering this treatment, these findings suggest that most participants were able to continue therapy without significant tolerability issues.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The majority of people taking part in the studies tolerated the medication well throughout the treatment period. For you, this is important because long-term management of atopic dermatitis often requires a treatment approach that can be maintained consistently.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These results support the feasibility of continuous upadacitinib therapy for suitable patients. When a treatment is both effective and manageable over time, it may help you maintain better control of your eczema symptoms and improve your overall quality of life.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Implications for Clinical Practice<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up trials confirmed that upadacitinib is an effective oral systemic treatment option for people with moderate-to-severe atopic dermatitis. If you are looking for alternatives to existing eczema therapies, these findings show that the medication can provide meaningful improvements in both symptoms and disease control.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The trials demonstrated rapid improvements in skin clearance, itch reduction and overall quality of life. For you, this could mean better control of uncomfortable symptoms and less disruption to your daily activities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">When selecting treatment, your clinician will consider factors such as your preferences, previous therapies and any other health conditions you may have. This personalised approach helps ensure that the treatment chosen is the most suitable option for your individual needs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Oral vs Injectable Options<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Upadacitinib offers the convenience of an oral treatment, providing an alternative to injectable biologics that may require regular injections or clinic visits. If you prefer taking a tablet rather than using an injectable therapy, this option may fit more easily into your daily routine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">An oral treatment approach may improve adherence and accessibility for some people. For you, having a simpler treatment method could make it easier to maintain your eczema management plan over the long term.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The availability of oral options also expands the range of systemic treatments for atopic dermatitis. This gives you and your clinician more flexibility to choose an approach that matches your symptoms, preferences and lifestyle.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Rapid Onset Benefits<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Early improvements in skin clearance and itch relief can have an important impact on how you experience your treatment. If you begin to notice changes within the first few weeks, this may encourage you to continue taking your medication and stay engaged with your care plan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Many patients experience meaningful symptom relief soon after starting treatment, helping reduce the burden of itching, inflammation and disrupted sleep. For you, faster improvement may make daily activities more comfortable and improve your overall wellbeing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A rapid response is especially valuable in chronic conditions such as atopic dermatitis, where symptoms can affect your confidence, comfort and quality of life. Effective early control may help you regain better management of your eczema over time.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Special Populations<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up trials included participants from diverse backgrounds, helping researchers understand how upadacitinib performs across a range of people with moderate-to-severe atopic dermatitis. However, further research is needed to better understand its use in groups such as older adults and people with multiple health conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If you belong to one of these groups, treatment decisions may need to be tailored more carefully to balance effectiveness and safety. Your clinician will consider your medical history, existing conditions and individual risk factors when deciding whether this treatment is appropriate for you.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ongoing monitoring remains an important part of care in these populations. Regular reviews help ensure that you continue to receive the benefits of treatment while any potential concerns are identified early.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Long-Term Management<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Atopic dermatitis is a long-term condition that often requires ongoing management rather than a one-time treatment approach. If you are using upadacitinib, it may form part of a broader care plan that includes moisturisers, trigger management and regular follow-up with your clinician.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Maintaining your treatment routine can help you achieve more consistent control of your eczema symptoms. For you, combining medication with good skin care habits may reduce the frequency of flare-ups and help protect your skin barrier over time.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Consistency is an important part of preventing flare recurrence. When you follow your personalised management plan, you give yourself the best opportunity to maintain symptom control and improve your overall quality of life.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Patient Education<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Patient education is an important part of successful eczema treatment. If you are starting upadacitinib, understanding how quickly you may see improvements and what to expect during treatment can help you feel more prepared and confident.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Although some symptoms may improve early, the full benefit of treatment may take several weeks to develop. For you, having realistic expectations can make it easier to stay consistent with your medication and understand that gradual improvement is often part of the process.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Clear information about your treatment can improve both adherence and satisfaction. When you understand how the medication works and what results to expect, you can take a more active role in managing your eczema.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Personalized Therapy<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Upadacitinib adds greater flexibility to personalised treatment strategies for moderate-to-severe atopic dermatitis. If you are considering this therapy, your clinician can take into account the severity of your eczema, your previous treatments and your individual goals when deciding whether it is suitable.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Treatment choices, including the dose and treatment approach, can be tailored according to your specific needs and response. For you, this personalised approach may help achieve better symptom control while balancing effectiveness, safety and convenience.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Shared decision-making is an important part of modern eczema care. When you are involved in discussions about your treatment options, you can make choices that better match your preferences and improve your overall treatment experience.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Monitoring Safety<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ongoing monitoring is an important part of treatment with upadacitinib, helping detect any potential side effects early. If you are taking this medication for moderate-to-severe atopic dermatitis, regular follow-up allows your clinician to make sure the treatment remains safe and suitable for you.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Monitoring may include blood tests, checks for infections and assessment of cardiovascular risk factors. For you, these reviews provide reassurance that your health is being carefully considered while you continue to receive treatment benefits.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Long-term studies are continuing to provide further information about the safety profile of upadacitinib. As more evidence becomes available, you and your clinician can make informed decisions about maintaining or adjusting your treatment plan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Overall Clinical Significance<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up 1 and Measure Up 2 trials showed that upadacitinib is an effective and generally well-tolerated oral treatment option for people with moderate-to-severe atopic dermatitis. If you are struggling to control your eczema with existing treatments, these findings may offer you another option to discuss with your clinician.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The trials demonstrated rapid improvement in symptoms, sustained effectiveness over time and the convenience of taking an oral medication. For you, this could mean better control of itching, inflammation and flare-ups while making your treatment routine easier to manage.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These results support the role of upadacitinib as an important addition to modern eczema care. When you discuss your options with your clinician, your symptoms, medical history and treatment preferences can help determine whether this approach is right for you.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Integration Into Clinical Practice<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"559\" src=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152057.233-1024x559.jpg\" alt=\"\" class=\"wp-image-6635\" srcset=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152057.233-1024x559.jpg 1024w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152057.233-980x535.jpg 980w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152057.233-480x262.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Clinicians can integrate upadacitinib into a wider treatment approach alongside topical therapies, moisturisers and supportive lifestyle measures. If you are considering this medication, it is important to understand that it is usually part of a personalised plan designed around your specific symptoms, health needs and treatment goals.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Upadacitinib may provide an alternative option for people who prefer an oral treatment or who have not achieved enough improvement with other systemic therapies. For you, having another treatment choice may make it easier to find an approach that balances effectiveness, convenience and tolerability.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Treatment decisions should always be individualised, taking into account your condition severity, medical history, preferences and response to previous treatments. A personalised strategy helps ensure that your care remains focused on achieving the best possible long-term outcomes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Future Research Directions<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ongoing studies will continue to explore the long-term effectiveness and safety of Upadacitinib in real-world populations. If you are considering this treatment, future research involving groups such as children, older adults and people with different health conditions may provide further insight into how widely it can be used.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Researchers are also investigating areas such as combination therapies and dose optimisation to understand how Upadacitinib may be used alongside other treatment approaches. For you, this could lead to more flexible treatment strategies that are better tailored to your individual needs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Continued research will help refine personalised approaches to <strong>atopic dermatitis<\/strong> care. As more evidence becomes available, you and your clinician may be able to make increasingly informed decisions about the most suitable treatment plan for your condition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Takeaways<\/strong>:<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Measure Up 1 and Measure Up 2 were pivotal Phase III studies evaluating oral upadacitinib for moderate-to-severe atopic dermatitis.<\/li>\n\n\n\n<li>Upadacitinib significantly improved eczema severity, itch and quality of life compared with placebo.<\/li>\n\n\n\n<li>Both 15 mg and 30 mg doses were effective, with greater efficacy generally seen at the higher dose.<\/li>\n\n\n\n<li>Many participants experienced rapid itch improvement within the first few weeks.<\/li>\n\n\n\n<li>Benefits were maintained during longer-term follow-up.<\/li>\n\n\n\n<li>Treatment decisions should always be individualised and made with an experienced dermatologist.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Myth vs Fact: Upadacitinib and the Measure Up Trials<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Myth<\/strong><\/td><td><strong>Fact<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Upadacitinib only improves skin redness.<\/td><td>The Measure Up trials demonstrated improvements in eczema severity, itch, sleep and quality of life.<\/td><\/tr><tr><td>Oral treatments always work more slowly than injections.<\/td><td>Upadacitinib produced rapid itch improvement in many participants, with some benefits seen within the first week.<\/td><\/tr><tr><td>Everyone with eczema can take upadacitinib.<\/td><td>Treatment suitability depends on age, disease severity, medical history and individual risk factors.<\/td><\/tr><tr><td>Once eczema improves, treatment can always be stopped.<\/td><td>Atopic dermatitis is a chronic disease and ongoing management may be needed.<\/td><\/tr><tr><td>Blood monitoring is unnecessary because it is a tablet.<\/td><td>Regular monitoring remains an important part of safe treatment with JAK inhibitors.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>FAQs:<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>1. What were the Measure Up 1 and Measure Up 2 trials?<br><\/strong>The Measure Up 1 and Measure Up 2 trials were large phase III clinical studies that evaluated the effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis. The trials assessed whether this oral JAK1 inhibitor could improve eczema severity, reduce itching and enhance quality of life compared with placebo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>2. What is upadacitinib and how does it work for atopic dermatitis?<br><\/strong>Upadacitinib is an oral selective JAK1 inhibitor that targets immune signalling pathways involved in eczema inflammation. By reducing the activity of these pathways, the treatment can help decrease redness, itching, inflammation and other symptoms associated with moderate-to-severe atopic dermatitis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>3. How effective was upadacitinib in the Measure Up trials?<br><\/strong>The Measure Up trials showed that upadacitinib significantly improved eczema severity compared with placebo at week 16. Many participants achieved EASI 75, EASI 90 and EASI 100 responses, meaning they experienced substantial improvements in their skin condition, including near-complete or complete clearance in some cases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>4. How quickly does upadacitinib improve eczema symptoms?<br><\/strong>Many participants experienced improvements in skin symptoms and itching within the first few weeks of treatment. While early changes can be encouraging, the full benefits of upadacitinib may continue to develop over several weeks or months with ongoing treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>5. What symptoms of atopic dermatitis can upadacitinib improve?<br><\/strong>Upadacitinib can help improve several important eczema symptoms, including itchy skin, redness, inflammation and visible lesions. The Measure Up trials also showed improvements in quality of life, which may help reduce the impact of eczema on sleep, daily activities and emotional wellbeing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>6. What doses of upadacitinib were studied in the Measure Up trials?<br><\/strong>The trials evaluated once-daily doses of 15 mg and 30 mg upadacitinib. Both doses showed significant benefits compared with placebo, although the higher dose generally produced greater improvements in eczema severity and itch reduction. Your clinician will consider your individual circumstances when deciding which dose is most appropriate.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>7. Is upadacitinib safe for treating moderate-to-severe eczema?<br><\/strong>Upadacitinib was generally well tolerated in the Measure Up trials, with most side effects being mild to moderate. Reported side effects included upper respiratory infections and headache, but regular monitoring is recommended to help manage potential risks during treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>8. Does treatment with upadacitinib require regular monitoring?<br><\/strong>Yes, ongoing monitoring is an important part of treatment with upadacitinib. Your clinician may recommend blood tests and regular reviews to check your response to treatment, monitor for possible side effects and ensure the medication remains suitable for your long-term care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>9. How is upadacitinib different from injectable eczema treatments?<br><\/strong>Upadacitinib is taken as a once-daily oral tablet, offering an alternative to injectable biologic therapies used for moderate-to-severe atopic dermatitis. For people who prefer tablets or want to avoid injections, an oral treatment may provide a more convenient approach to managing eczema.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>10. Who may benefit from upadacitinib treatment?<br><\/strong>Upadacitinib may be considered for adults and adolescents with moderate-to-severe atopic dermatitis who need systemic treatment. The most suitable option depends on factors such as eczema severity, previous treatments, overall health, potential risks and personal treatment preferences, which should be discussed with a dermatologist.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Final Thoughts: Advancing Atopic Dermatitis Care with Upadacitinib<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Measure Up 1 and Measure Up 2 trials have provided important evidence showing how upadacitinib may improve the management of moderate-to-severe atopic dermatitis. With its oral dosing, rapid symptom improvement and positive effects on skin clearance, itching and quality of life, this treatment represents a valuable addition to the growing range of eczema therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As treatment options continue to expand, personalised care remains essential. The right approach depends on the severity of your eczema, previous treatments, overall health and individual preferences. Working with an experienced dermatologist can help you understand whether upadacitinib or another treatment option may be suitable for your needs. <a href=\"https:\/\/www.london-dermatology-centre.co.uk\/\">If you would like to book a consultation with one of our dermatologists in London<\/a>, you can contact us at the London Dermatology Centre.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>References:<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>National Institute for Health and Care Excellence (2022) Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. Technology appraisal guidance TA814. Available at: <a href=\"https:\/\/www.nice.org.uk\/guidance\/ta814?utm_source=chatgpt.com\">https:\/\/www.nice.org.uk\/guidance\/ta814<\/a><\/li>\n\n\n\n<li>Guttman-Yassky, E., Teixeira, H.D., Simpson, E.L. et al. (2021) \u2018Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis: Results from the Measure Up 1 and Measure Up 2 randomised, double-blind, placebo-controlled phase 3 trials\u2019, The Lancet, 397(10290), pp.2151\u20132168. Available at: <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0140673621005882\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0140673621005882<\/a><\/li>\n\n\n\n<li>Lytvyn, Y., Mufti, A., Abduelmula, A., Sachdeva, M., Maliyar, K., Georgakopoulos, J.R. and Yeung, J. (2022) \u2018Efficacy and safety of upadacitinib for management of moderate-to-severe atopic dermatitis: An evidence-based review\u2019, Pharmaceutics, 14(11), article 2452. Available at: <a href=\"https:\/\/www.mdpi.com\/1999-4923\/14\/11\/2452\">https:\/\/www.mdpi.com\/1999-4923\/14\/11\/2452<\/a><\/li>\n\n\n\n<li>Simpson, E.L., Prajapati, V.H., Leshem, Y.A. et al. (2024) \u2018Upadacitinib rapidly improves patient-reported outcomes in atopic dermatitis: 16-week results from phase 3 clinical trials Measure Up 1 and 2\u2019, Dermatology and Therapy, 14(5), pp.1127\u20131144. Available at: <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11116320\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11116320\/<\/a><\/li>\n\n\n\n<li>Prajapati, V.H. et al. (2024) \u2018Sustained improvements over 140 weeks in signs, symptoms and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: Integrated results from the phase 3 Measure Up 1 and Measure Up 2 studies\u2019, British Journal of Dermatology, 191, Available at: <a href=\"https:\/\/academic.oup.com\/bjd\/article-abstract\/191\/Supplement_2\/ljae266.070\/7728639\">https:\/\/academic.oup.com\/bjd\/article-abstract\/191\/Supplement_2\/ljae266.070\/7728639<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition that can cause intense itching, dry skin, redness and repeated flare-ups. If you are living with moderate-to-severe eczema, these symptoms can affect your comfort, sleep, confidence and the way you manage everyday activities. When eczema becomes more difficult to control, topical treatments alone [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":6637,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6626","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/imagess-2026-07-13T152950.709-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/category\/uncategorized\/\" rel=\"category tag\">Uncategorized<\/a>","rttpg_excerpt":"Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition that can cause intense itching, dry skin, redness and repeated flare-ups. If you are living with moderate-to-severe eczema, these symptoms can affect your comfort, sleep, confidence and the way you manage everyday activities. When eczema becomes more difficult to control, topical treatments alone&hellip;","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6626"}],"version-history":[{"count":4,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6626\/revisions"}],"predecessor-version":[{"id":6642,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6626\/revisions\/6642"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6637"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}